Search
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Oxyphenbutazone
go.drugbank.com/drugs/DB03585ApprovedWithdrawnOxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022. … [A251600] Olipudase alfa works to hydrolyze sphingomyelin accumulated in body tissues, such as the lungs, liver, spleen, kidneys, and bone marrow.
Ethyl biscoumacetate
go.drugbank.com/drugs/DB08794ApprovedWithdrawnIt has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Rivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalFDA approved on July 1, 2011. … Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food.
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Products: XADAGO 100 MG TABLETASRECUBIERTAS CON PELÍCULA, XADAGO 50 MG TABLETAS RECUBIERTAS CON PELÍCULAZoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigational[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. … [A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone DiseasesStrontium chloride Sr-89
go.drugbank.com/drugs/DB09498Approved[A31264] Bone metastases is a common and severe complication presented in advanced stages of the disease. … Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases.
Categories: Pain Palliation (Bone Seeking Agents)Filgrastim
go.drugbank.com/drugs/DB00099ApprovedInvestigational[A245858] Tbo-filgrastim was approved by the FDA on August 29, 2012.[L36325] Filgrastim-sndz was approved on March 6, 2015 [L40768] and filgrastim-ayow was approved on March 2, 2022. … [L40714] Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow.